Promed Bioscience, a biotech company specializing in advanced collagen-based biomaterials for regenerative medicine, has successfully closed a €1.25 million growth financing round led by KV Fund II.
Overall, the investment emphasises KVF II’s commitment to supporting pioneering Cypriot companies with global potential.
This new capital injection will enable Promed to expand production capacity, scale its U.S. commercial activities, and further its entry into international markets, while continuing to advance its
